Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Fig. 1

Levels of anti-RBD antibodies at the first and second assessment according to medication group. The orange bars show anti-RBD levels at the first assessment and the purple bars show anti-RBD at the second assessment, 6–48 and 49–123 days after the second vaccine dose, respectively. Bars indicate the lower and upper quartiles. Horizontal lines inside the bars indicate the median. Vertical lines through the bars show the minimum (Q1−1.5×IQR) and maximum value (Q3+1.5×IQR). Dots indicate outliers. A cut-off at 200 BAU/ml is indicated by a red line. MTX mono, methotrexate monotherapy; ILi, interleukin inhibitors including tocilizumab, ustekinumab, iksekizumab, risankizumab, secukinumab; VED, vedolizumab; JAKi, janus kinase inhibitor; TNFi mono, tumor necrosis factor inhibitor in monotherapy; TNFi comb, tumor necrosis factor inhibitor in combination with metabolite inhibitor(s) or vedolizumab; RTX, rituximab. All groups include patients using prednisolone in doses <10mg/day in combination with other medication

Back to article page